A recent pilot study by researchers from Thompson Rivers University (TRU) and the University of British Columbia (UBC) Okanagan explored how medically supervised marijuana use might support individuals undergoing treatment for substance use disorders in a residential recovery setting.
The research focused on the experiences of both residents and staff when cannabis was included as part of a recovery plan.
Participants shared that marijuana helped ease symptoms like depression, anxiety, pain, and sleep problems—issues that often make recovery harder. Some also reported fewer cravings for opioids and other addictive substances.
According to Dr. Zach Walsh, a psychology professor involved in the study, these effects suggest that cannabis could help people stick with their recovery programs by making both mental and physical challenges more manageable.
While the findings are encouraging, the researchers noted that stigma remains a big hurdle. Many staff members were skeptical about cannabis as a valid medical tool. Dr. Florriann Fehr, a nursing professor and co-lead on the study, emphasized the importance of educating staff to break down these barriers. “Misinformation and outdated views can prevent cannabis from being used effectively, even when it shows potential,” she added.
The research was carried out at Maverick Supportive Recovery, a live-in recovery facility situated in British Columbia offering structured care for those dealing with substance use. The program creates a stable environment designed to help people recover in a safe and supportive setting.
Although the initial results are positive, the team behind the study says broader research is needed. The authors noted that there is no one-size-fits-all solution, as recovery looks different for everyone, and what works for one person may not work for another. But if cannabis can help someone stay in treatment and manage their symptoms, it’s worth exploring further.
Ultimately, they noted that cannabis is not a replacement for traditional treatments but an additional option that could help certain individuals, especially when used under medical supervision.
To help reduce stigma and share knowledge, events like public forums and professional gatherings are being organized. Dr. Fehr is scheduled to present the study’s findings in June at a global nursing conference in Helsinki. In addition, Thompson Rivers University will host a Medical Cannabis and Recovery forum this April, welcoming the public, healthcare workers, and researchers interested in learning more about this topic.
The study was funded by the British Columbia Ministry of Health and the Interior Universities Research Coalition.
The findings of this small study could suggest to marijuana industry firms like Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) that there is still plenty of room to bring to market innovative cannabis products tailored to the needs of different groups of patients concerned about particular symptoms.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
